期刊文献+

吉林大学第一医院住院患者质子泵抑制剂应用分析 被引量:5

Utilization of Proton Pump Inhibitors in The Inpatients of The First Hospital of Jilin University
下载PDF
导出
摘要 目的:了解2011年1月—2011年12月我院住院患者质子泵抑制剂使用情况及用药趋势,为临床合理用药提供参考。方法:采用用药频度(DDDs)排序与销售金额排序法,并对我院2011年质子泵抑制剂的DDDs、销售金额、限定日费用(DDC)进行统计与分析。结果:我院注射用质子泵抑制剂的用量与DDDs远远大于口服制剂,注射用质子泵抑制剂的同步性比口服制剂的同步性好。结论:建议医院制定质子泵抑制剂合理应用指南,临床用药严格把握用药指征,避免过度使用。 OBJECTIVE :The investigate the status quo and tendency of the utilization of proton pump inhibitors in our hospital during Jan. -Dec. period of 2011 for reference of clinical rational use of drug. METHODS: The use of proton pump inhibitors in our hospital in 2011 was analyzed statistically in respect of DDDs, consumption sum and DDC by using the methods of DDDs ranking and consumption sum ranking. RESULTS: The consumption quantity and DDDs of the proton pump inhibitors for injection were significantly higher than those of the oral proton pump inhibitors, and the proton pump inhibitors for injection showed better synchronism than did oral proton pump inhibitors. CONCLUSION : It is recommended that guidelines for rational use of proton pump inhibitors be established in hospital and mediation indications should be followed strictly in clinical use to avoid excessive use of proton pump inhibitors.
出处 《中国医院用药评价与分析》 2013年第10期886-888,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 药物利用 质子泵抑制剂 合理用药 Drug utilization Proton pump inhibitors Rational use of drug
  • 相关文献

参考文献4

二级参考文献15

共引文献35

同被引文献45

  • 1段若竹,吴剑波.免疫增强剂的研究应用及展望[J].国外医药(抗生素分册),2006,27(2):54-57. 被引量:19
  • 2陈新谦,金有豫,汤光主编.新编药物学[M].第17版.北京:人民卫生出版社,2010:253-272.
  • 3陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 4国家药典委员编.国家药典[S].北京:人民卫生出版社,2010:1-2.
  • 5FDA.Drug Safety Communication:Clostridium difficileassociated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors(PPI)[EB/OL].http://www.fda.gov/Drugs/Drug Safety/ucm290510.htm,2012-02-08/2013-07-01.
  • 6ASHP.ASHP therapeutic guidelines on stress ulcer prophylaxis ASHP commission on therapeutics and approved by the ASHP board of directors on November14,1998[J].Am J Health Syst Pharm,1999,56(4):347-379.
  • 7Allen M E,Kopp B J,Erstad B L.Stress ulcer prophylaxis in the postoperative period[J].Am J Health Syst Pharm,2004,61(6):588-596.
  • 8Grube R R,May D B.Stress ulcer prophylaxis in hospitalize patients not inintensive care units[J].Am J Health Syst Pharm,2007,64(3):1396-1400.
  • 9Guillamondegui O D,Gunter O L Jr,Bonadies J A.et al.Practice management guidelines for stress ulcer prophylaxis[EB/OL].http://www.east.org/trp/strssulcer.pdf,2008.
  • 10Elliott M,Antman E.ACCF/ACG/AHA 2010expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines:A focused update of the 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID uses[J].J Am Coll Cardiol,2010,56(24):2051-2066.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部